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INTRODUCTION
Common anticancer strategies often fail resulting in tumor recur-
rences and metastasis. Only about 6% of colorectal cancer (CRC) 
metastatic patients live more than 5 years after diagnosis.1 There 
is an urgent need to develop molecularly targeted cancer thera-
pies and drug-screening models to stratify patients and achieve 
maximum benefit from expensive treatments. The recent advent 
of organoid (mini-gut) culture has allowed development of an in 
vitro model that mimics many aspects of colon/intestinal homoeo-
stasis and tumors.2–7 Sato and colleagues,7 initially established the 
ideal conditions for isolated small intestinal crypts or single leu-
cine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5),8 
positive stem cells to develop into organoids: laminin-rich Matrigel 
mimicking the basal lamina and a finely balanced medium includ-
ing R-spondin1 (Wnt agonist),9 Noggin (BMP antagonist)10 and 
epidermal growth factor,11 were found sufficient to maintain the 
proliferation of the stem cell compartment or single Lgr5-positive 
cells. Similar to small intestine, the stem cell compartment at the 
base of the crypt-like domain of the mini-guts maintains epithelial 
turnover: stem cells give rise to progenitor cells, which differenti-
ate while migrating toward the villus-like domain into enterocytes, 
enteroendocrine cells, and goblet cells. Paneth cells, instead, are 
located at the bottom of the crypt. In the organoid model, tumor 
cells can grow in a more similar manner to that in living organisms, 
with cell-cell interactions and boundaries. The modeling of cancer 
mutations in human intestinal/colon organoids using new tools for 
gene manipulation, allowed both in vitro and in vivo experimental 
approaches for mutational and functional analysis.3–5 Organoid cul-
ture can be used indefinitely. Moreover, changes in the composi-
tion of the medium can drive changes in phenotype/structure of 
organoids that facilitates in vitro testing of drugs, inhibitors, and 
growth factors. This model may also present a novel method of drug 
screening.4,12
One of the key cellular mechanisms of regulating activity of 
transcriptional-activators is through protein degradation using 
the ubiquitin-proteasome system. Specificity of proteolysis for any 
particular substrate is determined by its association with a specific 
E3-receptor subunit. FBXW7 (also called hCDC4, Ago, Sel10, and 
Fbw7) functions as a receptor subunit for the Skp1/Cullin/F-box 
(SCF)-E3-ubiquitin-ligase (SCFFBXW7). Recent excellent reviews on 
FBXW7 confirm that loss of FBXW7 function is likely to result in 
failed regulation of its downstream proteins targets, which disrupt 
a variety of critical signaling pathways resulting in acquisition of the 
hallmarks of cancer.13–20 Underlining the importance of FBXW7 as a 
tumor suppressor is the fact that loss of function mutations in the 
FBXW7 gene occur in a variety of human cancers including 10–15% 
of CRCs.21–23
We and others have previously studied the Fbxw7 conditional 
knockout in murine intestinal lineages and cancer.24,25 The syn-
ergistic contribution of FBXW7 and TP53 to the suppression of 
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gastrointestinal cancer has also been reported.26,27 Interestingly, an 
intestinal knock-in model of Fbxw7 (R482Q) mutation has recently 
been described,28 nevertheless both Fbxw7 conditional knockout 
and knock-in models promote an equivalent intestinal tumorigen-
esis on an adenomatous polyposis coli (Apc) mutant background.25,28 
FBXW7 mutations have been investigated comprehensively in 
CRC.23,29 Understanding FBXW7 loss-associated mechanism(s) driv-
ing drug resistance could therefore be important to successfully 
target and eradicate CRC cells carrying FBXW7 mutations. Recent 
literature has reported FBXW7 loss confers resistance to oxaliplatin 
and cisplatin chemotherapeutic agents,30,31 while CRC cell lines har-
boring FBXW7 mutations or deletions are sensitive to Rapamycin 
treatment.32
Here, we employed the murine intestinal organoid system, to 
identify cellular response mediated by Fbxw7 to various concen-
trations of 5-fluorouracil (5-FU), a DNA damage agent commonly 
administered to metastatic CRC patients.1 We show that fbxw7 gut-
specific inactivation (fbxw7ΔG) with high proliferative capacity give 
rise to microadenoma-like structures. 5-FU promotes terminal differ-
entiation and apoptosis in control floxed-fbxw7 (fbxw7fl/fl) organoids. 
Intestinal organoids from fbxw7ΔG are two to three times less sensi-
tive to 5-FU treatment than fbxw7fl/fl intestinal organoids. Moreover, 
epithelial cells extravasated from the fbxw7ΔG organoids were abro-
gated by the 5-FU treatment, and the induction of cell differentiation.
RESULTS
FBXW7 loss in human CRC cells promotes resistance to 5-FU
The chemotherapeutic agent 5-FU is used to treat many different 
types of cancer, including gastrointestinal cancers. In vitro, 5-FU 
can trigger apoptosis in CRC cells and it appeared to be initiated 
by caspase-dependent death pathway.33,34 To investigate the role 
of FBXW7 mutation in drug resistance, we examined the induction 
of growth inhibition in a dose-dependent manner using FBXW7 
knockout HCT116 (HCT116FBXW7(−/−)) and DLD-1 (DLD-1FBXW7(−/−)),23,24 
in parallel with FBXW7 wild-type (FBXW7(+/+)) counterpart cell lines 
(Figure 1a and Supplementary Figure S1a). Seeded cells were syn-
chronized overnight by serum starvation to reduce the FBXW7 
deficiency-induced cell division/growth in CRC cells, as reported 
previously,23,24,30,32,35 prior to 72 hours incubation with 5-FU for cyto-
toxicity assay. Sulforhodamine B colorimetric assay was carried out 
to measure the IC50. IC50 of HCT116
FBXW7(−/−) cells (14.3 μmol/l) was 
twofold higher than the IC50 of HCT116
FBXW7(+/+) cells (7.1 μmol/l) 
(Figure 1b,c). In addition, the colony-forming efficiency assay 
revealed that HCT116FBXW7(−/−) exhibited a significant resistance 
to 5-FU (Figure 1d,e). In accordance with previous studies using 
oxaliplatin and cisplatin,30,31 deletion of FBXW7 mediated higher 
tolerance of 5-FU in HCT116 cells. To test whether re-expression of 
FBXW7 render CRC cells sensitive to 5-FU, as Fbxw7α was shown 
to be the preferentially expressed Fbxw7 isoform in intestine/
colon,24 we have overexpressed FBXW7α in both HCT116FBXW7(−/−) 
and DLD-1FBXW7(−/−) cells. CRC cell lines are initially transfected with 
FLAG-FBXW7α and control pcDNA3 plasmids in 10 cm tissue culture 
plates. Ten hours after transfection, cells were split and seeded in 
96-well plates. Transfection efficiency was determined by western 
blot (Supplementary Figure S1f). Cells were synchronized after over-
night serum starvation, treated with increasing concentrations of 
the 5-FU for 72 hours and the IC50 was determined using sulforho-
damine B assay as outlined above (Figure 1f,g and Supplementary 
Figure S1d,e). The results showed that Fbxw7α overexpression sig-
nificantly decreased the 5-FU IC50 and inhibited FBXW7 mutation in 
mediating 5-FU drug-resistance of CRC cell lines.
Fbxw7ΔG organoids (mini-guts) possess a peculiar morphology
We have demonstrated intense fbxw7-expression in the crypt 
base of wild-type mice, including the transit amplifying/progeni-
tor cells, compared with the villus using in-situ hybridization.24,25 
Intestinal fbxw7 knockout resulted in impaired cell differentiation, 
with a reduction in the number of goblet and Paneth cells. However, 
despite the increase of actively proliferating epithelial cells in the 
guts of the fbxw7ΔG mice, no intestinal tumors were reported up 
to 11–12 months of age. This could be because—in the guts mul-
tiple signaling molecules are emerging from different linages—the 
underlying mesenchyme, immune and crypt-based epithelial cells 
may together cooperate tightly to control transformation of intes-
tinal epithelial cells. Recently, Paneth cells were shown to be a criti-
cal component of the intestinal epithelial stem cell niche36; though 
the depletion of Paneth cells failed to alter significantly the crypt 
phenotype.37 In addition, the crypt culture recapitulates the cellular 
diversity, resembling proliferative and differentiated compartments 
of the intestinal epithelium without coculturing with stromal/fibro-
blast cells. Thus, to explore the function of murine epithelial Fbxw7, 
we cultured intestinal organoids from fbxw7fl/fl and villin-Cre+:fbxw7fl/
fl (fbxw7ΔG) mice (Supplementary Figure S2a,b).
Small intestinal crypts isolated from fbxw7fl/fl mice gave rise to 
enterospheres, spherical organoids formed by a monolayer of epi-
thelial cells, within a few hours following seeding. On day 4 of growth, 
most of the fbxw7fl/fl enterospheres were fully branched organoids 
(defined enteroids),38 and characterized by the presence of buds 
(Figure 2a,b). Morphology of the fbxw7fl/fl organoids represent a 
normal intestinal organoid culture system which contains crypt and 
villus domains without a mesenchymal component.7 A low percent-
age of cystic organoids with an empty lumen, (defined spheres), 
were also present (17%). Moreover after 7 days of culture, fbxw7fl/fl 
organoids have mainly manifested by enteroids (Figure 2a). In con-
trast, Fbxw7 inactivation accelerated organoid growth and altered 
the phenotype of intestinal organoids (Figure 2a,c). Large fbxw7ΔG 
organoids were however followed by releasing clusters of cells out-
side the organoid lumen after 3 days of culture (Supplementary 
Video S1). Histologically, this peculiar morphology is highly vari-
able in appearance, resembling a microadenoma appearance.39 
After 7 days of culture, almost all of the fbxw7ΔG enterospheres had 
changed to microadenoma-like shape (Figure 2a). Reculturing the 
released cells from fbxw7ΔG organoids, demonstrated an abnormally 
high proliferative activity and adapted cancer cells properties (data 
not shown).
Loss of Fbxw7 in intestinal organoid induces resistance to 5-FU
To test the loss of FBXW7 function as a potential mechanism of drug 
resistance, we next performed 5-FU toxicity assay in fully structured 
enteroids. In addition, according to a recent report,12 the intestinal 
organoids are three to four times more sensitive than CRC cell lines. 
Thus, both fbxw7fl/fl and fbxw7ΔG organoids were exposed to the esti-
mated IC50 of HCT116
FBXW7(+/+) cells, 7.5 μmol/l 5-FU (Figure 1c), along 
with 2.5 and 0.8 μmol/l 5-FU (Figure 3a). We and other groups previ-
ously showed that the deficiency of murine intestinal Fbxw7 induced 
cell division via Ki67 immunohistochemistry and BrdU labelling.24,25 
Therefore, to exclude the potential effect of cell proliferation, the 
5-FU treatment started after 2 days for fbxw7ΔG organoids, whereas 
for the fbxw7fl/fl organoids after 3 days (Figure 3a). The toxicity assay 
showed that mini-guts harboring fbxw7 deletion were approximately 
two to three times less sensitive to 5-FU treatment than intestinal 
organoids from fbxw7fl/fl mice (Figure 3b,c), likewise HCT116FBXW7(−/−) 
and DLD-1FBXW7(−/−) cells (Figure 1b,c and Supplementary Figure S1). 
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These results have confirmed the crucial role of Fbxw7 inactivation 
in the acquisition of drug resistance. Furthermore, we have com-
pared the morphology of organoids treated with 5-FU by counting 
the number of viable organoids per each category; enterospheres, 
enteroids, spheres, and microadenoma-like structure. Quantification 
revealed that 5-FU promoted large spheres versus enteroids, in a 
dose-dependent manner, in both wild-type fbxw7fl/fl and fbxw7ΔG 
mutant organoids after 72 hours (Figure 3d–f). Although the high-
est concentration of 5-FU (7.5 μmol/l) induced the death of most of 
the organoids, the remaining viable organoids were spheres only. 
Notably, the number of microadenoma-like structures from fbxw7ΔG 
mutant organoids significantly decreased in response to 5-FU 
(Figure 3d,e and Supplementary Video S2). These findings together 
suggest that 5-FU-induced DNA damages may cause a reduction in 
cellular proliferation resulting in morphological changes within the 
mini-gut structure. In this regard, as the proliferative compartment 
is predominantly in the crypt-like domains, its impairment may lead 
to spherical mini-guts. These results support the hypothesis that 
the organoids can be used as ex vivo tools for investigating drug 
resistance.
Figure 1  FBXW7 deletion confers 5-FU resistance to human colon cancer HCT116 cells. (a) RT-PCR shows FBXW7 status in HCT116FBXW7(+/+) and 
HCT116FBXW7(−/−) cell lines. Reverse primer was designed to target the deleted exon 5 of FBXW7. (b,c) Sulforhodamine B (SRB) assay to test the cytotoxicity 
of 5-FU in both HCT116FBXW7(+/+) and HCT116FBXW7(−/−) cell lines. Vehicle (dimethyl sulfoxide) and 10 doses of 5-FU (from 0.05 to 100 μmol/l) were incubated 
for 72 hours following cell synchronization. (d,e) Colony-forming efficiency assay of HCT116FBXW7(+/+) and HCT116FBXW7(−/−) cell lines. 0, 2.5, and 7.5 μmol/l 
5-FU was replaced after 72 hours incubation with fresh medium. At day 10 of growth, colonies were stained with crystal violet and counted by ImageJ. 
(f,g) Cytotoxicity of 5-FU was analyzed via SRB assay following transient transfection of HCT116FBXW7(−/−) cells with pcDNA3 (control) or FLAG-FBXW7α 
plasmids as previously described.30 IC50 values, indicated in the table, were calculated via GraphPad Prism software. Experiments were performed in 
triplicate and repeated at least in three independent occasions. Data are mean ± standard error of the mean (*P < 0.05, **P < 0.01, ***P < 0.001).
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Fbxw7 loss counteracts organoids differentiation induced by 5-FU
To examine the effects of 5-FU on proliferation and differentiation, 
surviving organoids were fixed, embedded in paraffin, and pro-
cessed for immunohistochemistry. As outlined above, a treatment 
with 7.5 μmol/l 5-FU induced cell death in almost but not all wild-
type fbxw7fl/fl organoids, and very few remaining live organoids 
formed spheres (Figure 3e), therefore we used the surviving organ-
oids treated with 2.5 and 0.8 μmol/l 5-FU. Previous studies reported 
that Fbxw7 loss in murine intestinal epithelium resulted a reduction 
in secretory cells together with an increase in actively cycling cells 
within the crypts.24,25 Consistent with this, by comparing untreated 
samples, fbxw7ΔG mini-guts exhibited a significantly lower per-
centage of secretory cells such as enteroendocrine cells positively 
stained for Chromogranin A (chg-A) (Figure 4a,b), goblet cells 
stained for mucin 2 (muc2) (Figure 4a,c) and Paneth cells stained 
for lysozyme (Figure 4a,d). Moreover, we examined whether there 
was correlation between Ki-67 proliferative activity and apoptosis 
in treated organoids. In line with previous studies of mouse mod-
els,24–26 we observed that the ratio between proliferative cells (Ki-67 
positive) and apoptotic cells (active caspase 3 positive) was higher 
in mutant mini-guts (Figure 4a,e). Interestingly, 5-FU treatment 
induced goblet, Paneth, and enteroendocrine cells differentiation in 
a concentration-dependent manner (Figure 4a–d), indicating that 
5-FU improves organoid peculiar structure by rescuing the cellular 
differentiation driven by loss of fbxw7. In addition, consistent with 
fbxw7ΔG mice,24,25 expression of secretory progenitor markers math-
1 (mouse atonal homologue-1) and ngn-3 (neurogenin-3) were also 
significantly repressed in organoids lacking of fbxw7 (Figure 5a). 
Interestingly, following 5-FU treatment, math1 and ngn3 expression 
was significantly increased about fourfolds in fbxw7ΔG mini-guts 
(Figure 5b), in contrast with a slight increase in fbxw7fl/fl mini-guts 
(Figure 5c). These data indicate that 5-FU promotes terminal differ-
entiation and apoptosis in normal intestinal epithelium, potentially 
by triggering the DNA damage/repair pathway. Also, CRC harbor-
ing FBXW7 mutations may acquire drug resistance via induction of 
proliferative progenitor cells and impairment of their terminal dif-
ferentiation in colon/intestine.
DISCUSSION
Murine intestinal fbxw7-deletion blocks differentiation and drives 
hyperproliferation in the intestine.24,25,28 In vitro studies also reported 
that loss of FBXW7 function leads to the acquisition of drug resis-
tance in CRC cell lines, through the induction of an epithelial- 
mesenchymal transition (EMT) pathway,32 and/or alteration of 
MCL1,40 mTOR,41 and TP53 status.30 In this study, to demonstrate 
that intestinal organoids are a useful and physiologically relevant 
model system to study the role of Fbxw7 in cancer biology and drug 
resistance, we have cultured organoids in the presence and absence 
of 5-FU. Due to their comparable structure and behavior,12,38 treated 
and untreated organoids (seeded initially with the same number of 
crypts) are analyzed across several key parameters over time; integ-
rity, morphology, survival and apoptosis, and stained for various 
intestinal cell lineages. Here, we describe that fbxw7ΔG organoids 
exhibited higher proliferative activity, thus driving faster matura-
tion of the enterospheres into enteroids and, ultimately microade-
noma-like structures, which disseminated cells outside the mini-gut 
lumen in a burst (Figure 2c and Supplementary Video S1).
Consistent with CRC cell lines, we further confirmed that Fbxw7 
deficiency confers higher tolerance to 5-FU, a DNA damaging 
agent; the IC50 of fbxw7 mutant mini-guts was significantly higher 
than controls (5.7 versus 2.6 μmol/l 5-FU, respectively) (Figure 3c). 
Analyzing the complex phenotypical changes in organoid culture, 
5-FU treatment induced the transformation of the common crypt-
villus morphology (enteroids) into cystic structures (spheres), in a 
dose-dependent manner (Figure 3d–f). Likewise the loss of Fbxw7-
induced cellular transformation, the transformation of enteroids 
into spheres was also found in Apc-inactivated intestinal organ-
oids,42 a key component of the Wnt/β-catenin signaling pathway in 
regulating intestinal epithelial homeostasis and the early stages of 
colorectal carcinogenesis.43 As predicted, the number of microad-
enoma-like mini-guts significantly decreased after 5-FU treatment 
(Figure 3e,f ). Fbxw7-depleted mini-guts, showed an active prolif-
erative compartment (Figure 4e) along with reduction of secretory 
progenitor cells (Figure 5a). According to these, loss of Fbxw7 leads 
Figure 2 fbxw7-null organoids grow faster and present microadenoma-
like morphology. (a) Percentage of enterosphere, enteroid, sphere, and 
microadenoma-like morphologies at day 4 and day 7 of growth of 
fbxw7fl/fl and fbxw7ΔG mini-guts. Mini-guts were counted by microscopy 
(*P < 0.05, **P < 0.01, ***P < 0.001). (b,c) Images are representative 
of fbxw7fl/fl and fbxw7ΔG mini-gut populations at day 4 of growth. 
Arrowheads indicate microadenoma-like mini-guts. Scale bars, 75 μm.
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to impaired intestinal terminal differentiation and therefore fbxw7ΔG 
organoids appears smaller than fbxw7fl/fl organoids. On the other 
hand, due to an early increased rate of proliferation, most of fbxw7ΔG 
organoids quickly enlarged and exploded. Consequently, fbxw7ΔG 
organoids were not homogeneous populations to quantify and 
compare their size with fbxw7fl/fl organoids.
Our experiments do not point to molecular mechanism under-
neath FBXW7-rendered resistance to 5-FU. The role of FBXW7 in drug 
resistance is just beginning to emerge. Based on our own and recent 
published studies, there is a strong link between FBXW7 and cell 
cycle regulation as well as the EMT-mediated drug resistance in can-
cer cells.30,32,40,44,45 However, beyond the scope of this current study 
and the importance of given data here and our published and unpub-
lished data on links between EMT and FBXW7, more recently, we have 
initiated a study using different approaches to explore molecular 
mechanism(s) underneath FBXW7-rendered resistance to DNA-
damage agents including 5-FU in CRC, organoid, and animal models. 
Our current analysis however highlights significant downregulation of 
the cyclin-dependent kinase inhibitor p21 in fbxw7ΔG organoids while 
the p53 related transcription factor p63 expression appeared to be not 
significantly changed. 5-FU led to the induction of p21 and p63 in wild-
type fbxw7fl/fl organoids but in fbxw7ΔG organoids induced p63 and not 
p21 (Supplementary Figure S3a–c). The differential expression of p53 
related genes further support the hypothesis of an existing relationship 
between mutated-Fbxw7 and p53 in response to drug treatment.30 
Previously published studies showed that p53 upregulates Fbxw727,46 
whereas it represses ZEB family transcriptional regulators (ZEB1 and 
ZEB2), implicated in EMT.47
These findings clearly indicated that the percentage of entero-
endocrine cells, goblet cells and Paneth cells were increased along 
Figure 3 fbxw7ΔG organoids tolerate higher dose of 5-FU. (a) Layout of the drug response experiments and following analysis considering faster 
growth of fbxw7ΔG mini-guts. (b,c) Toxicity assay of 5-FU in fbxw7fl/fl and fbxw7ΔG mini-guts and IC50 values. (d,e) Morphological analysis following 
72 hours incubation with 0.8, 2.5, and 7.5 μmol/l 5-FU. Percentage of enterosphere, enteroid, sphere, and microadenoma-like morphologies was 
assessed by microscopy in fbxw7fl/fl and fbxw7ΔG mini-gut populations. (f) Images represent phenotypical changes of both fbxw7fl/fl and fbxw7ΔG mini-
guts in response to 5-FU. Scale bars, 50 μm. Experiments were performed in triplicate and repeated at least in two independent occasions (*P < 0.05, 
**P < 0.01, ***P < 0.001).
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with a reduction of cycling versus apoptotic cell ratio following 
5-FU-mediated DNA damage. Fbxw7 depletion was found to influ-
ence cell commitment and proliferation in murine intestinal epi-
thelium via activation of c-Jun and Notch signaling pathways.24,25,28 
However, since the amount of proteins available for extraction from 
5-FU-treated organoids, it is difficult to analyze how 5-FU modu-
lates math1 and ngn3 in organoids. Previously published reports 
indicated that intestinal Notch activation upregulates Hes-1 and 
consequently, represses the transcription of math1 and ngn3.48,49 
Therefore, protein extracts were isolated from untreated and 5-FU 
treated HCT116 and DLD-1 cell lines with FBXW7(−/−) and FBXW7(+/+) 
alleles and Western blotted for active NICD1 antibody, as a FBXW7 
target for degradation.50 These observation further support that 
expression level of active NICD1 is increased in FBXW7(−/−) cells 
while decreased in both FBXW7(+/+) and FBXW7(−/−) cells treated with 
5-FU (Supplementary Figure S4a). We have also studied the relative 
mRNA expression of MATH1 and NGN3 genes by quantitative real-
time polymerase chain reaction in CRC cell lines. Unfortunately with 
both Cyber green and TaqMan assays, Ct values of MATH1 and NGN3 
were >32 (representing even higher Ct value than FBXW7 gene in 
K/O cells). We have additionally increased the amount of cDNA 
which had also no effect on Ct value (Supplementary Figure S4c). 
These suggest that MATH1 and NGN3 are very low expressed genes 
in these cells and may not be reliable to calculate their relative gene 
expression for the purpose of the experiment. In addition, terminal 
differentiation of the enteroendocrine producing cells has been 
shown by coordinating transcription of the secretin gene with cell 
cycle arrest.51,52 Hence, the modulation of Math1 and ngn3 by 5-FU 
could also be linked to the changes of cyclin-dependent kinase 
inhibitor p21 level as outlined above (Supplementary Figure S3b,c). 
However, further studies should be carried out in future, to further 
precisely explore these possibilities via loss and gain of functional 
analysis. Progenitor cells, abundant in fbxw7ΔG mini-guts, may drive 
tumor recurrences and/or metastasis post-treatment. However, 
contrary to the organoid model, the fbxw7ΔG mice alone did not 
promote intestinal tumorigenesis up to 11–12 months of age,24,25 
whereas we predict that this genotype causes sufficient functional 
rearrangement to promote/recapitulate human tumorigenesis. 
Figure 4 Fbxw7 loss impairs 5-FU-induced differentiation and, thus, apoptosis. (a) H&E staining and immunohistochemistry (IHC) analysis of 
enteroendocrine cells positive for chromogranine A (chgA), goblet cells positive for mucine (muc2), Paneth cells positive for lysozyme (lys), cycling cells 
(Ki67), and apoptotic cells positive for active caspase 3 (active cas 3) on fbxw7fl/fl and fbxw7ΔG mini-guts following incubation with 0.8 μmol/l 5-FU. Black 
arrowheads show positively stained cells. Scale bars, 50 μm. (b–d) Histograms show percentage of terminally differentiated cells and ratio between 
cycling cells and apoptotic cells (e) following IHC analyses. The relative number of positively stained cells in 50-untreated organoids was counted for 
each genotype (fbxw7fl/fl versus fbxw7ΔG mini-guts) and in 30-treated organoids for each dose of 5-FU and presented as % of positively stained cells to 
the total number of cells (*P < 0.05, **P < 0.01, ***P < 0.001).
H&E
Enteroendocrine cells Goblet cells
12
10
8
6
4
Ch
gA
+
 
ce
lls
 (%
)
2
0
12
10
8
6
4
M
uc
2+
 
ce
lls
 (%
)
2
0
0 0.8
Concentration 5-FU (μmol/l)
2.5 0 0.8
Concentration 5-FU (μmol/l)
2.5 0 0.8
Concentration 5-FU (μmol/l)
2.5 0 0.8
Concentration 5-FU (μmol/l)
2.5
12 60
50
40
30
20
10
0
10
8
6
4
Ly
so
zy
m
e+
 
ce
lls
 (%
)
ki
67
+
 
ce
lls
/%
 a
ct
ive
ca
sp
as
e-
3+
 c
el
ls 
(%
)
2
0
Paneth cells Proliferation/apoptosis
***
***
**
*
*
*
**
*
*
0
0.
8
0
0.
8
fb
xw
7f
l/f
l
fb
xw
7Δ
G
fbxw7 fl/fl fbxw7 ΔG fbxw7 fl/fl fbxw7 ΔG fbxw7 fl/fl fbxw7 ΔG
fbxw7 (fl/fl)
fbxw7 (ΔG)
ChgA Muc2 Lysozyme Ki67 Active cas3a
b c d e
7Modeling drug treatment response in organoid culture
F Lorenzi et al.
Molecular Therapy — Methods & Clinical Development (2016) 16024Official journal of the American Society of Gene & Cell Therapy
Nevertheless, the organoid culture method allows a specific analy-
sis of epithelial components of the intestine/colon and therefore 
these changes in morphology suggest an alteration between prolif-
erative and differentiating compartments, induced independently 
of intestinal microenvironment.
We conclude that Fbxw7-mutated cancer cells are highly prolif-
erative and resistant to the terminal differentiation and subsequent 
cell death that is normally triggered by chemotherapeutic DNA 
damage (Figure 5d). Furthermore, DNA damaging agents could 
cause mutations in cycling cells promoting the acquisition of pro-
survival properties in drug-resistant cancer cells.53,54 Our findings 
suggest that a differentiation therapy may be one strategy to vali-
date current chemotherapeutic drugs against the FBXW7-mutated 
CRCs. These results support the hypothesis that human mini-guts 
derived from cancer patients,4 and/or the modeling of cancer muta-
tions in human intestinal/colon organoids using new tools for gene 
manipulation,3,5 may allow both ex vivo and in vivo experimental 
approaches investigating drug resistance, drug screening, and 
preclinical toxicological studies in molecularly targeted systems 
that mimic endogenous cancer driver mutations and eventually 
design efficacious cancer-specific drugs.
MATERIALS AND METHODS
Mouse lines
Both fbxw7fl/fl and fbxw7ΔG were described previously.24 Only same sex lit-
termates of 4–6-week mice were used. Mice were housed and bred in a 
pathogen-free transgenic animal facility of the Biomedical Service Unit and 
all procedures complied with regulations and guidelines of the Biomedical 
Service Unit, University of Nottingham.
Small intestine crypt isolation and organoid culture
Small intestine was resected from fbxw7fl/fl and fbxw7ΔG mice.7,24 Intestine 
was repeatedly washed with cold phosphate-buffered saline, then longi-
tudinally opened and sectioned in small fragments. Crypts were released 
from the  epithelium by incubation with 3 mmol/l ethylenediaminetet-
raacetic acid phosphate-buffered saline for 35 minutes at 4 °C. Following 
counting and isolation by centrifuge, crypts were resuspended with 
Figure 5 5-FU treatment promotes secretory progenitor cells in absence of Fbxw7. (a) fbxw7, math1, and ngn3 expression was analyzed by quantitative 
real-time polymerase chain reaction (qRT-PCR) in fbxw7ΔG mini-guts at day 7 of growth. Expression level was first normalized to β-actin and then to 
fbxw7fl/fl mini-guts. (b,c) math1 and ngn3 expression was analyzed by qRT-PCR in fbxw7fl/fl and fbxw7ΔG mini-guts after 72 hours treatment with 0.8 μmol/l 
5-FU. Expression was first normalized to β-actin and then to the corresponding untreated mini-guts (*P < 0.05, **P < 0.01, ***P < 0.001). (d) Schematic 
shows 5-FU induction of terminal differentiation and apoptosis in fbxw7ΔG mini-guts.
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Matrigel (BD Biosciences, Oxford, UK), seeded into a 48-well plate and fed 
with advanced Dulbecco’s modified eagle medium/F-12 medium con-
taining; N2 supplement (Invitrogen, Warrington, UK), B27 supplement 
(Invitrogen), 1 mmol/l N-acetylcysteine (Sigma-Aldrich, Dorset, UK), 50 ng/
ml murine recombinant epidermal growth factor (Invitrogen), 100 ng/ml 
Noggin (Peprotech, London, UK), and 1 μg/ml R-Spondin1.7 0.8, 2.5, and 
7.5 μmol/l 5-FU (Tocris Bioscience, Bristol, UK) was administered at day 3 or 
day 4 of growth respectively to fbxw7ΔG and fbxw7fl/fl mini-guts, for viability 
and morphological analyses in response to drug treatment. Organoid were 
also monitored with integrated optics for phase-contrast imaging and 
machine vision technology in a humidified, 5% CO2 atmosphere at 37 °C 
for 5 days (Cell-IQ, CM Technologies Oy; www.c-mtechnologies.com). Media 
replaced every 48 hours and images captured automatically per well at half 
an hour intervals. Cell-IQ analyzer software was used according to manufac-
turer’s instructions.
Cell culture, transfection, and western blotting analysis
Human colon cancer HCT116 and DLD-1 cells were fed with RPMI-1640 
medium supplemented with 10% fetal bovine serum (Sigma-Aldrich) and 
2 mmol/l L-glutamine (Life Technologies, Warrington, UK). Transfection of 
CRC cell lines with DNA plasmids was performed via Lipofectamine 3000 
(Invitrogen) transfection reagent following the manufacturer’s instructions. 
RIPA lysis buffer supplemented with protease inhibitor cocktail was used to 
extract the protein content from both live and dead cells. Equal amount of 
total proteins was denaturized, loaded into a 10% sodium dodecyl sulfate-
polyacrylamide gradient gel for separation and then transferred overnight 
to polyvinylidene fluoride membranes. Membranes were blocked with 3% 
bovine serum albumin in Tris-buffered saline and probed with different anti-
bodies as indicated as previously described.30
Cytotoxicity assay and colony-forming efficiency assay
Human colon cancer HCT116 and DLD-1 cells were fed with RPMI-1640 
medium supplemented with 10% fetal bovine serum (Sigma-Aldrich) and 
2 mmol/l L-glutamine (Life Technologies). 3,000 cells/well were seeded for 
cytotoxicity assay into 96-well plate in triplicate, synchronized by serum-
starvation, and incubated with increasing concentrations of 5-FU for 
72  hours. Cells were fixed with 6% trichloroacetic acid for 1 hour at 4 °C 
and then washed with water. 0Air dried plates were stained with 0.4% (w/v) 
sulforhodamine B in acetic acid for 20 minutes at room temperature and 
washed five times with 1% acetic acid. 10 mmol/l Trizma base was added 
and the absorbance read at 540 nm.30
To perform colony-forming efficiency assay, 500 cells (HCT116) were 
seeded into a six-well plate in triplicate. Then, 0, 2.5, and/or 7.5 μmol/l 5-FU 
was administered prior to cell-doubling, to reduce survival advantages asso-
ciated to different proliferative capabilities. 72 hours after, 5-FU containing 
medium was replaced with a complete culture medium. Colonies were fixed 
with 4% paraformaldehyde for 20 minutes at room temperature and stained 
with 0.1% crystal violet for the following procedures to count number of 
colonies using Image J software.30
Immunohistochemistry
Organoids were fixed in 4% paraformaldehyde overnight at 4 °C and resus-
pended in 2% low-melting agarose prior to paraffin embedding. 4-μm 
sections were cut and processed for immunohistochemistry analysis or 
Hematoxylin and Eosin (H&E) staining as previously reported.24 The fol-
lowing primary antibodies were used: active caspase 3 (R&D systems, 
Abingdon, UK), Chromogranin A and Ki-67 (Abcam, Cambridge, UK), Mucin 
2 (Santa Cruz Biotechnology, Heidelberg, Germany), and Lysozyme (Dako, 
Cambridge, UK).
Quantitative real-time polymerase chain reaction analysis
To dissociate the Matrigel, organoids were incubated with cell recovery solu-
tion (Corning, Corning, NY) for 3 hours in cold room. Total RNA was separated 
by using TRIZOL reagent (Sigma-Aldrich) and precipitated following manu-
facturer’s instructions. cDNA synthesis was obtained by using PrimeScript 
Reverse Transcriptase (TAKARA, Saint-Germain-en-Laye, France) according 
to the manufacturer’s instructions. Quantitative real-time polymerase chain 
reaction was performed based on the incorporation of SYBR green (Life 
Technologies). Primers24 used are listed in Supplementary Table S1.
Statistics
All statistical analyses were evaluated with Student’s t-tests and the Mann-
Whitney U-test, as appropriate. A P value of < 0.05 was considered statisti-
cally significant, where experiments were repeated at least two and three 
times in triplicates, respectively.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGMENTS
We thank B. Vogelstein for providing HCT116 knockout cells, and N. Li and P. Clarke 
for technical advice, M. Ahmed for reading the manuscript, and the fantastic fundrais-
ing efforts of Alison Sims and her family in memory of Daz Sims to support the work 
in our laboratory. This study was supported by Cancer Research UK, research projects 
A9275 and A10247, and the University of Nottingham Vice Chancellor’s Scholarship for 
Research Excellence (European Union).
REFERENCES
 1. Stintzing, S (2014). Management of colorectal cancer. F1000Prime Rep 6: 108.
 2. Barker, N, Ridgway, RA, van Es, JH, van de Wetering, M, Begthel, H, van den Born, M et al. 
(2009). Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457: 608–611.
 3. Matano, M, Date, S, Shimokawa, M, Takano, A, Fujii, M, Ohta, Y et al. (2015). Modeling 
colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal 
organoids. Nat Med 21: 256–262.
 4. van de Wetering, M, Francies, HE, Francis, JM, Bounova, G, Iorio, F, Pronk, A et al. 
Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 
2015, 161: 933–945.
 5. Drost, J, van Jaarsveld, RH, Ponsioen, B, Zimberlin, C, van Boxtel, R, Buijs, A et al. (2015). 
Sequential cancer mutations in cultured human intestinal stem cells. Nature 521: 43–47.
 6. Sato, T and Clevers, H (2013). Growing self-organizing mini-guts from a single intestinal 
stem cell: mechanism and applications. Science 340: 1190–1194.
 7. Sato, T, Vries, RG, Snippert, HJ, van de Wetering, M, Barker, N, Stange, DE et al. (2009). 
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. 
Nature 459: 262–265.
 8. Barker, N, van Es, JH, Kuipers, J, Kujala, P, van den Born, M, Cozijnsen, M et al. (2007). 
Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 
1003–1007.
 9. de Lau, W, Peng, WC, Gros, P and Clevers, H (2014). The R-spondin/Lgr5/Rnf43 module: 
regulator of Wnt signal strength. Genes Dev 28: 305–316.
 10. McMahon, JA, Takada, S, Zimmerman, LB, Fan, CM, Harland, RM and McMahon, AP 
(1998). Noggin-mediated antagonism of BMP signaling is required for growth and 
patterning of the neural tube and somite. Genes Dev 12: 1438–1452.
 11. Normanno, N, De Luca, A, Bianco, C, Strizzi, L, Mancino, M, Maiello, MR et al. (2006). 
Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2–16.
 12. Grabinger, T, Luks, L, Kostadinova, F, Zimberlin, C, Medema, JP, Leist, M et al. (2014). Ex 
vivo culture of intestinal crypt organoids as a model system for assessing cell death 
induction in intestinal epithelial cells and enteropathy. Cell Death Dis 5: e1228.
 13. Wang, Z, Inuzuka, H, Fukushima, H, Wan, L, Gao, D, Shaik, S et al. (2012). Emerging roles of 
the FBW7 tumour suppressor in stem cell differentiation. EMBO Rep 13: 36–43.
 14. Welcker, M and Clurman, BE (2008). FBW7 ubiquitin ligase: a tumour suppressor at the 
crossroads of cell division, growth and differentiation. Nat Rev Cancer 8: 83–93.
 15. Wang, Z, Inuzuka, H, Zhong, J, Wan, L, Fukushima, H, Sarkar, FH et al. (2012). Tumor 
suppressor functions of FBW7 in cancer development and progression. FEBS Lett 586: 
1409–1418.
 16. Kitagawa, K, Kotake, Y and Kitagawa, M (2009). Ubiquitin-mediated control of oncogene 
and tumor suppressor gene products. Cancer Sci 100: 1374–1381.
 17. Cheng, Y and Li, G (2012). Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer 
Metastasis Rev 31: 75–87.
 18. Tan, Y, Sangfelt, O and Spruck, C (2008). The Fbxw7/hCdc4 tumor suppressor in human 
cancer. Cancer Lett 271: 1–12.
 19. Davis, RJ, Welcker, M and Clurman, BE (2014). Tumor suppression by the Fbw7 ubiquitin 
ligase: mechanisms and opportunities. Cancer Cell 26: 455–464.
 20. Cremona, CA, Sancho, R, Diefenbacher, ME and Behrens, A (2016). Fbw7 and its 
counteracting forces in stem cells and cancer: Oncoproteins in the balance. Semin Cancer 
Biol 36: 52–61.
 21. Sjöblom, T, Jones, S, Wood, LD, Parsons, DW, Lin, J, Barber, TD et al. (2006). The consensus 
coding sequences of human breast and colorectal cancers. Science 314: 268–274.
 22. Cancer Genome Atlas Network. Comprehensive molecular characterization of human 
colon and rectal cancer. Nature 2012, 487: 330–337.
 23. Rajagopalan, H, Jallepalli, PV, Rago, C, Velculescu, VE, Kinzler, KW, Vogelstein, B et al. 
(2004). Inactivation of hCDC4 can cause chromosomal instability. Nature 428: 77–81.
9Modeling drug treatment response in organoid culture
F Lorenzi et al.
Molecular Therapy — Methods & Clinical Development (2016) 16024Official journal of the American Society of Gene & Cell Therapy
 24. Babaei-Jadidi, R, Li, N, Saadeddin, A, Spencer-Dene, B, Jandke, A, Muhammad, B et al. 
(2011). FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, 
Jun, and DEK for degradation. J Exp Med 208: 295–312.
 25. Sancho, R, Jandke, A, Davis, H, Diefenbacher, ME, Tomlinson, I and Behrens, A (2010). F-
box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment 
and is a haploinsufficient tumor suppressor. Gastroenterology 139: 929–941.
 26. Grim, JE, Knoblaugh, SE, Guthrie, KA, Hagar, A, Swanger, J, Hespelt, J et al. (2012). Fbw7 
and p53 cooperatively suppress advanced and chromosomally unstable intestinal 
cancer. Mol Cell Biol 32: 2160–2167.
 27. Yokobori, T, Mimori, K, Iwatsuki, M, Ishii, H, Onoyama, I, Fukagawa, T et al. (2009). p53-
Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 
69: 3788–3794.
 28. Davis, H, Lewis, A, Behrens, A and Tomlinson, I (2014). Investigation of the atypical FBXW7 
mutation spectrum in human tumours by conditional expression of a heterozygous 
propellor tip missense allele in the mouse intestines. Gut 63: 792–799.
 29. Kemp, Z, Rowan, A, Chambers, W, Wortham, N, Halford, S, Sieber, O et al. (2005). CDC4 
mutations occur in a subset of colorectal cancers but are not predicted to cause loss of 
function and are not associated with chromosomal instability. Cancer Res 65: 11361–11366.
 30. Li, N, Lorenzi, F, Kalakouti, E, Normatova, M, Babaei-Jadidi, R, Tomlinson,  I et al. 
(2015). FBXW7-mutated colorectal cancer cells exhibit aberrant expression of 
phosphorylated-p53 at serine-15. Oncotarget 6: 9240–9256.
 31. Song, Y, Zhou, X, Bai, W and Ma, X (2015). FBW7 increases drug sensitivity to cisplatin 
in human nasopharyngeal carcinoma by downregulating the expression of multidrug 
resistance-associated protein. Tumour Biol 36: 4197–4202.
 32. Wang, Y, Liu, Y, Lu, J, Zhang, P, Wang, Y, Xu, Y et al. (2013). Rapamycin inhibits FBXW7 loss-
induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in 
colorectal cancer cells. Biochem Biophys Res Commun 434: 352–356.
 33. Bunz, F, Hwang, PM, Torrance, C, Waldman, T, Zhang, Y, Dillehay, L et al. (1999). Disruption 
of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 
263–269.
 34. Mhaidat, NM, Bouklihacene, M and Thorne, RF (2014). 5-Fluorouracil-induced apoptosis 
in colorectal cancer cells is caspase-9-dependent and mediated by activation of protein 
kinase C-δ. Oncol Lett 8: 699–704.
 35. Mao, JH, Perez-Losada, J, Wu, D, Delrosario, R, Tsunematsu, R, Nakayama, KI et al. (2004). 
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 
432: 775–779.
 36. Sato, T, van Es, JH, Snippert, HJ, Stange, DE, Vries, RG, van den Born, M et al. (2011). Paneth 
cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469: 415–418.
 37. Durand, A, Donahue, B, Peignon, G, Letourneur, F, Cagnard, N, Slomianny, C et al. 
(2012). Functional intestinal stem cells after Paneth cell ablation induced by the loss of 
transcription factor Math1 (Atoh1). Proc Natl Acad Sci USA 109: 8965–8970.
 38. Stelzner, M, Helmrath, M, Dunn, JC, Henning, SJ, Houchen, CW, Kuo, C et al.; NIH Intestinal 
Stem Cell Consortium. (2012). A nomenclature for intestinal in vitro cultures. Am J Physiol 
Gastrointest Liver Physiol 302: G1359–G1363.
 39. Tierney, RP, Ballantyne, GH and Modlin, IM (1990). The adenoma to carcinoma sequence. 
Surg Gynecol Obstet 171: 81–94.
 40. Wertz, IE, Kusam, S, Lam, C, Okamoto, T, Sandoval, W, Anderson, DJ et al. (2011). 
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 
471: 110–114.
 41. Mao, JH, Kim, IJ, Wu, D, Climent, J, Kang, HC, DelRosario, R et al. (2008). FBXW7 targets 
mTOR for degradation and cooperates with PTEN in tumor suppression. Science 321: 
1499–1502.
 42. Onuma, K, Ochiai, M, Orihashi, K, Takahashi, M, Imai, T, Nakagama, H et al. (2013). Genetic 
reconstitution of tumorigenesis in primary intestinal cells. Proc Natl Acad Sci USA 110: 
11127–11132.
 43. Fodde, R and Brabletz, T (2007). Wnt/beta-catenin signaling in cancer stemness and 
malignant behavior. Curr Opin Cell Biol 19: 150–158.
 44. Inuzuka, H, Shaik, S, Onoyama, I, Gao, D, Tseng, A, Maser, RS et al. (2011). SCF(FBW7) 
regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. 
Nature 471: 104–109.
 45. Zhou, X, Jin, W, Jia, H, Yan, J and Zhang, G (2015). MiR-223 promotes the cisplatin 
resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7. 
J Exp Clin Cancer Res 34: 28.
 46. Matsumoto, A, Onoyama, I and Nakayama, KI (2006). Expression of mouse Fbxw7 
isoforms is regulated in a cell cycle- or p53-dependent manner. Biochem Biophys Res 
Commun 350: 114–119.
 47. Kim, T, Veronese, A, Pichiorri, F, Lee, TJ, Jeon, YJ, Volinia, S et al. (2011). p53 regulates 
epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp 
Med 208: 875–883.
 48. Fre, S, Huyghe, M, Mourikis, P, Robine, S, Louvard, D and Artavanis-Tsakonas, S (2005). 
Notch signals control the fate of immature progenitor cells in the intestine. Nature 435: 
964–968.
 49. Jensen, J, Pedersen, EE, Galante, P, Hald, J, Heller, RS, Ishibashi, M et al. (2000). Control of 
endodermal endocrine development by Hes-1. Nat Genet 24: 36–44.
 50. O’Neil, J, Grim, J, Strack, P, Rao, S, Tibbitts, D, Winter, C et al. (2007). FBW7 mutations in 
leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase 
inhibitors. J Exp Med 204: 1813–1824.
 51. Mutoh, H, Naya, FJ, Tsai, MJ and Leiter, AB (1998). The basic helix-loop-helix protein BETA2 
interacts with p300 to coordinate differentiation of secretin-expressing enteroendocrine 
cells. Genes Dev 12: 820–830.
 52. Ratineau, C, Petry, MW, Mutoh, H and Leiter, AB (2002). Cyclin D1 represses the basic 
helix-loop-helix transcription factor, BETA2/NeuroD. J Biol Chem 277: 8847–8853.
 53. Blanpain, C, Mohrin, M, Sotiropoulou, PA and Passegué, E (2011). DNA-damage response 
in tissue-specific and cancer stem cells. Cell Stem Cell 8: 16–29.
 54. Metcalfe, C, Kljavin, NM, Ybarra, R and de Sauvage, FJ (2014). Lgr5+ stem cells 
are indispensable for radiation-induced intestinal regeneration. Cell Stem Cell 14: 
149–159.
This work is licensed under a Creative Commons Attribution 4.0 
International License. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in 
the credit line; if the material is not included under the Creative Commons license, users will 
need to obtain permission from the license holder to reproduce the material. To view a copy 
of this license, visit http://creativecommons.org/licenses/by/4.0/
Supplementary Information accompanies this paper on the Molecular Therapy—Methods & Clinical Development website (http://www.nature.com/mtm)
